文献速递瓣膜病与结构性心脏病

依格列汀对主动脉瓣钙化进展的影响

Effect of Evogliptin on the Progression of Aortic Valvular Calcification.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

本研究为多中心、双盲、安慰剂对照、分层随机、平行、治疗探索性临床试验,纳入228例主动脉瓣狭窄患者,随机分为安慰剂组、依格列汀5mg组和10mg组。主要终点96周主动脉瓣钙体积变化在依格列汀组与安慰剂组间无显著差异;但18F-NaF PET测量的48周活动性钙化体积变化在依格列汀组显著低于安慰剂组。结论认为该探索性研究未证实依格列汀对主动脉瓣钙化的保护作用,但PET结果提示需更大规模验证。

要点

  • 依格列汀5mg和10mg均未显著改善96周主动脉瓣钙体积变化。
  • 依格列汀组48周18F-NaF PET活动性钙化体积变化显著低于安慰剂组。
  • 安慰剂组48至96周钙体积增加较基线至48周更明显,依格列汀组此趋势被抑制。

核心结论

  • 探索性研究未证明依格列汀对主动脉瓣钙化进展具有保护作用。
  • 18F-NaF PET的有利结果及依格列汀组可能随用药时间延长抑制钙化提示需更大规模验证试验。

研究设计与样本

  • 多中心、双盲、安慰剂对照、分层随机、平行、治疗探索性临床试验。
  • 共纳入228例主动脉瓣狭窄患者,年龄67±11岁,女性占33%。
  • 随机分为安慰剂组(n=75)、依格列汀5mg组(n=77)和依格列汀10mg组(n=76)。

主要发现

  • 96周主动脉瓣钙体积变化:依格列汀5mg与安慰剂差异-5.27(95%CI:-55.36至44.82,P=0.84)。
  • 96周主动脉瓣钙体积变化:依格列汀10mg与安慰剂差异-18.83(95%CI:-32.43至70.10,P=0.47)。
  • 安慰剂组48至96周钙体积增加136 mm3(95%CI:108-163)高于基线至48周的102 mm3(95%CI:75-129),P=0.0485。
  • 48周18F-NaF PET活动性钙化体积变化:依格列汀5mg组较安慰剂组低-1,325.6(95%CI:-2,285.9至-365.4,P=0.008)。
  • 48周18F-NaF PET活动性钙化体积变化:依格列汀10mg组较安慰剂组低-1,582.2(95%CI:-2,610.8至-553.5,P=0.0038)。

临床怎么用

  • 依格列汀目前不推荐用于延缓主动脉瓣钙化进展的常规治疗。
  • 18F-NaF PET可评估活动性钙化,但需结合更大规模试验确认其临床价值。

局限性

  • 本研究为探索性研究,样本量有限。
  • 主要终点未达显著差异,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medical therapy for aortic stenosis (AS) remains an elusive goal. OBJECTIVES: This study sought to establish whether evogliptin, a dipeptidyl peptidase-4 inhibitor, could reduce AS progression. METHODS: A total of 228 patients (age 67 ± 11 years; 33% women) with AS were randomly assigned to receive placebo (n = 75), evogliptin 5 mg (n = 77), or evogliptin 10 mg (n = 76). The primary endpoint was the 96-week change in aortic valve calcium volume (AVCV) on computed tomography. Secondary endpoints included the 48-week change in active calcification volume measured using 18F-sodium fluoride positron emission tomography (18F-NaF PET). RESULTS: There were no significant differences in the 96-week changes in AVCV between evogliptin 5 mg and placebo (-5.27; 95% CI: -55.36 to 44.82; P = 0.84) or evogliptin 10 mg and placebo (-18.83; 95% CI: -32.43 to 70.10; P = 0.47). In the placebo group, the increase in AVCV between 48 weeks and 96 weeks was higher than that between baseline and 48 weeks (136 mm3; 95% CI: 108-163 vs 102 mm3; 95% CI: 75-129; P = 0.0485). This increasing trend in the second half of the study was suppressed in both evogliptin groups. The 48-week change in active calcification volume on 18F-NaF PET was significantly lower in both the evogliptin 5 mg (-1,325.6; 95% CI: -2,285.9 to -365.4; P = 0.008) and 10-mg groups (-1,582.2; 95% CI: -2,610.8 to -553.5; P = 0.0038) compared with the placebo group. CONCLUSIONS: This exploratory study did not demonstrate the protective effect of evogliptin on AV calcification. Favorable 18F-NaF PET results and possible suppression of aortic valve calcification with longer medication use in the evogliptin groups suggest the need for larger confirmatory trials. (A Multicenter, Double-blind, Placebo-controlled, Stratified-randomized, Parallel, Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-1229 in Patients With Calcific Aortic Valve Disease; NCT04055883).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Song JK, Lee S, Kim YJ, et al. Effect of Evogliptin on the Progression of Aortic Valvular Calcification. J Am Coll Cardiol. 2024. PMID: 39260927. doi:10.1016/j.jacc.2024.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。